Navigation Links
Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
Date:3/14/2017

SAN DIEGO, March 14, 2017 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced the appointment of Alexey Vinogradov, Ph.D., to its board of directors. Dr. Vinogradov currently serves as Head of Pharmstandard Ventures, a corporate venture fund of Pharmstandard Group, until recently known as Inbio Ventures, where he served as a Managing Partner and CEO. Dr. Vinogradov replaces Dr. Andrei Petrov as a director of the company.

"We are excited to have Alexey join our board during this exciting time of Avelas' corporate development," said Carmine Stengone, president and CEO of Avelas Biosciences. "Alexey has considerable experience in research and development, operations and business development, and I'm confident he will contribute meaningfully to our future success."

Dr. Vinogradov has over 15 years of experience at different positions in the biotech industry. He has served as a board member at Argos Therapeutics, as a board observer at Protagonist Therapeutics and Aquinox, and currently serves as a board observer at Allena Pharmaceuticals. Prior to joining Inbio Ventures in 2012, as co-founding partner and CBO, Dr. Vinogradov was involved in portfolio building at Bioprocess Capital Partners. He also led the fundraising and served in the executive management of Promogene, Tartis-Oncology and Everon. In addition, Dr. Vinogradov was involved in a range of business development activities at Bioprocess Group.

Dr. Vinogradov held a postdoctoral position at the Laboratory of Biomolecular Sciences, Wageningen University, Netherlands. He obtained his Ph.D. degree in Biochemistry and MS degree in Chemistry from Moscow State University.

About Avelas Biosciences

Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. The initiation of a Phase 2 clinical trial for AVB-620 in breast cancer is expected in the first half of 2017. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avelas-biosciences-appoints-alexey-vinogradov-phd-to-board-of-directors-300423042.html


'/>"/>
SOURCE Avelas Biosciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Avelas Biosciences to Present at 28th Annual Roth Conference
2. Representative Scott Peters Visits Avelas Biosciences
3. Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients
4. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
5. Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
6. DuPont Industrial Biosciences Leader Presents Major Advances in Biomaterials at 2017 Advanced Bioeconomy Leadership Conference
7. Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation
8. ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
9. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
10. Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
11. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... Equipment for the Semiconductor, MEMS, and Microfluidics Industries, announces the new Model 800E ... found more often in automated production mask aligners. OAI has already received ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... Electrospinning and Electrospraying line of nanofiber and nanoparticle fabrication ... for the lab to fully automated pilot plants and equipment for industrial ...
(Date:8/16/2017)... MN (PRWEB) , ... August 16, 2017 , ... ... our third U.S. Food and Drug Administration (FDA) inspection at our Dilworth, MN ... No 483 was issued. This inspection was conducted as part of a routine ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kapstone Medical ... years of successes helping medical technology companies and inventors develop and safeguard their latest ... full-service national engineering firm with a portfolio of clients in the United States and ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):